Image of father laughing with his sons

GSK Co-pay Assistance Programs

This GSK Co-pay Assistance Program can help eligible patients with their out-of-pocket costs for certain GSK prescription medicines.

You might be eligible for this program if:

  • Have a commercial medical or prescription insurance plan; or
  • Are uninsured;
    AND
  • Are a resident of the US (including the District of Columbia, Puerto Rico, and the US Virgin Islands); and
  • Are not eligible for or enrolled in a government funded program
Women talk outside

Select an option below to learn more.

  • Rx-logo BENLYSTA and NUCALA

    BENLYSTA Co-pay Assistance Program

    NUCALA Co-pay Assistance Program

    Assistance is available in Spanish and many other languages

    La asistencia está disponible en español y muchos otros idiomas

    Full Terms and Conditions

    Eligibility criteria
    Patients may be eligible based on general eligibility criteria below:

    • Patient has a commercial medical or prescription insurance plan; or
    • Patient is uninsured;

    AND

    • Patient is a resident of the US (including the District of Columbia, Puerto Rico, and the US Virgin Islands); and
    • Not eligible for or enrolled in a government funded program that provides prescription drug coverage*

    To determine if a patient is eligible for the BENLYSTA or NUCALA (herein "GSK") Co-pay Program, an enrollment from must be completed and submitted to the Co-pay Program. The Co-pay Program will evaluate the patient for eligibility and communicate eligibility to the patient and provider. Eligibility in the GSK Co-pay Program is for one year. Patients must qualify for the Co-pay Program each year that they wish to participate in the Program. Final patient eligibility determinations are provided by the GSK Co-pay Program.

    *Patients are not eligible for this program if they are covered by any federal or state prescription insurance program. This includes patients enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare. This may also include state pharmaceutical assistance programs and other federal or state plans not listed. Patients are also ineligible for this program if they are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Patients enrolled in a state or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash paying) patient. Those on Medicare Part D, even if in the coverage gap, are not eligible. Patients enrolled in private indemnity or HMO insurance plans that reimburse them for the entire cost of their prescription drugs are also not eligible.

    Patients must have a prescription for the GSK Product in order to apply for the GSK Co-pay Program. If patient's prescription drug coverage is provided by a private commercial payer and the commercial payer has opted out of the GSK Co-pay Program, the patient is not eligible to participate.

    The GSK Co-pay Program is not insurance. GSK reserves the right to rescind, revoke, or amend this offer without notice at any time. Offer good only in the United States (including the District of Columbia, Puerto Rico and the US Virgin Islands). Void where prohibited, taxed, or otherwise restricted by law.

    Program Details
    If the patient is approved, the GSK Co-pay Program may help with the patient's cost share for the GSK product, and the cost of administration, up to $100 per administration, up to a program total of $15,000 annually. Residents of Massachusetts, Minnesota or Rhode Island, are not eligible for reimbursement of administrative fees. Doctor's office visits, labs, and other ancillary services are not included in the Co-Pay Program.

    Patients should inform Program representatives of any changes in insurance coverage during the course of enrollment in the GSK Co-pay Program.

  • Rx logo BLENREP, JEMPERLI, and ZEJULA

    BLENREP, JEMPERLI, and ZEJULA Co-pay Program

    Assistance is available in Spanish and many other languages

    La asistencia está disponible en español y muchos otros idiomas

    Full Terms and Conditions

    Eligibility criteria

    Patients may be eligible based on general eligibility criteria below:

    • Patients have a commercial medical or prescription insurance plan; or
    • Are uninsured;

    AND

    • Are a resident of the US (including the District of Columbia, Puerto Rico, and the US Virgin Islands); and
    • Are 18 years or older
    • Not eligible for or enrolled in government funded programs that provide prescription drug coverage*

    Application Process

    To determine if your patient may be eligible for the Together with GSK Oncology Co-pay Program, you and your patient will need to complete the program application.

    For ZEJULA
    Patients and prescribers must:

    For BLENREP and JEMPERLI
    Patients and prescribers must:

    Once the application is received, the Together with GSK Oncology Co-pay Program will evaluate the patient for eligibility and communicate eligibility. Eligibility in the Together with GSK Oncology Co-pay Program is for one year. Patients must apply for Co-pay assistance each year that they wish to participate in the Program. Final patient eligibility determinations are provided by the Together with GSK Oncology HUB.

    *Patients are not eligible for this program if they are covered by any federal or state prescription insurance program. This includes patients enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare. This may also include state pharmaceutical assistance programs and other federal or state plans not listed. Patients are also ineligible for this program if they are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Patients enrolled in a state or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash paying) patient. Those on Medicare Part D, even if in the coverage gap, are not eligible. Patients enrolled in private indemnity or HMO insurance plans that reimburse them for the entire cost of their prescription drugs are also not eligible.

    Patients must have a prescription for a GSK Oncology product in order to apply for the Together with GSK Oncology Co-pay Program. If the patient's prescription drug coverage is provided by a private commercial payer and the commercial payer has opted out of the Together with GSK Oncology Co-pay Program, the patient is not eligible to participate.

    The Together with GSK Oncology Co-pay Program is not insurance. GSK reserves the right to rescind, revoke, or amend this offer without notice at any time. Offer good only in the United States (including the District of Columbia, Puerto Rico and the US Virgin Islands). Void where prohibited, taxed, or otherwise restricted by law.

    Program Details

    For ZEJULA
    If the patient is approved, the Together with GSK Oncology Co-pay Program may help with the patient's cost share for the GSK Oncology product.

    Doctor's office visits, labs, and other ancillary services are not included in the Co-Pay Program.

    The patient should inform Program Representatives of any changes in insurance coverage during the course of enrollment in the Together with GSK Oncology Co-pay Program.

    For BLENREP and JEMPERLI
    If the patient is approved, the Together with GSK Oncology Co-pay Program may help with the patient's cost share for the GSK Oncology product and may also cover the cost of administration, up to $100 per administration for patients prescribed BLENREP and JEMPERLI, up to a program total of $26,000 annually. Residents of Massachusetts, Minnesota or Rhode Island, are not eligible for reimbursement of administration fees.

    Doctor's office visits, labs, and other ancillary services are not included in the Co-Pay Program.

    Patients should inform Program Representatives of any changes in insurance coverage during the course of enrollment in the Together with GSK Oncology Co-pay Program.

  • Rx logo Co-pay Program for patients treated with GSK COVID Treatment

    Full Terms and Conditions

    Eligibility criteria

    Patients may be eligible based on general eligibility criteria below:

    • Have a commercial medical or prescription insurance plan; and
    • Are a resident of the US (including the District of Columbia, Puerto Rico, and the US Virgin Islands); and
    • Are not eligible for or enrolled in a government funded programs
    • Have not been treated with product from the inventory purchased by the US government

    Patients who have insurance coverage provided through any type of state-, federal-, or government funded program (e.g., Medicare, Medicaid, Tricare, VA) are not eligible to participate in the GSK Co-pay Program. Patients who have been treated with product that has been purchased by the United States government are not eligible for the GSK Co-Pay Program. Medicare eligible patients who are enrolled in a government subsidized retiree prescription drug benefit plan or an employer group waiver health plan are also ineligible for the Co-pay program. (Most patients become eligible for Medicare when they reach age 65.)

    If a patient’s drug coverage is provided by a private commercial payer and the commercial payer has opted out of the GSK Co-pay Program, patient is not eligible to participate.

    To determine eligibility for the GSK Co-pay Program for COVID patients, patients must submit an Enrollment Form which is available on the patient website. The Program will evaluate the patient for eligibility and communicate eligibility to the patient. Patients must have been treated and paid out-of-pocket costs for the GSK Product in order to apply for the GSK Co-pay Program. Claims must be submitted to the Program within 90 days from the date the Explanation of Benefits was issued.

    The GSK Co-pay Program is not insurance. GSK reserves the right to rescind, revoke, or amend this offer without notice at any time. Offer good only in the United States (including the District of Columbia, Puerto Rico and the US Virgin Islands). Void where prohibited, taxed, or otherwise restricted by law.

    Program Details

    If patients are approved, the GSK Co-pay Program may help with the patient’s cost share for the GSK product, and the patient’s cost share for administration, up to $100 per administration, up to a program total of $2,000. Residents of Massachusetts, Minnesota or Rhode Island, are not eligible for reimbursement of administrative fees. Doctor's office visits, labs, and other ancillary services are not included in the Co-pay Program.